Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Centre Hospitalier Universitaire De Bordeaux maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 3 pending office actions. These matters are distributed across 3 distinct art units and involve 3 distinct examiners. GZYBOWSKI, MICHAEL STANLEY is the busiest examiner for the portfolio, holding 1 busiest examiner pending action.
The distribution of 3 pending office actions across 3 distinct art units indicates a broad technical range within the Biotechnology & Pharmaceuticals sector. Because there are 3 distinct examiners, practitioners must manage three separate prosecution tracks. GZYBOWSKI, MICHAEL STANLEY, who handles 1 busiest examiner pending action, is just one of the individuals whose examination style must be considered. This decentralized structure across different art units may lead to varied outcomes and requires a versatile strategy to address the 3 pending office actions effectively. Practitioners should focus on the specific procedural history of the 3 pending office actions to ensure consistency across the 3 distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GZYBOWSKI, MICHAEL STANLEY | 1 | 67.6% | +52.2% |
| DICKINSON, PAUL W | 1 | 63.2% | +9.6% |
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18549899 | EX VIVO METHOD FOR ANALYSING A TISSUE SAMPLE USING PROTEOMIC PROFILE MATCHING, AND ITS USE FOR THE DIAGNOSIS, PROGNOSIS OF PATHOLOGIES AND FOR PREDICTING RESPONSE TO TREATMENTS | GZYBOWSKI, MICHAEL STANLEY | — |
| 17778941 | BIOCOMPATIBLE OILY FERROFLUID AND PREPARATION PROCESS | DICKINSON, PAUL W | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17593380 | CAPTURE OF MICROVESICLES FOR DIAGNOSTIC PURPOSES | COUGHLIN, MATTHEW P | 72d overdue |
| 18549899 | EX VIVO METHOD FOR ANALYSING A TISSUE SAMPLE USING PROTEOMIC PROFILE MATCHING, AND ITS USE FOR THE DIAGNOSIS, PROGNOSIS OF PATHOLOGIES AND FOR PREDICTING RESPONSE TO TREATMENTS | GZYBOWSKI, MICHAEL STANLEY | — |
| Art Unit | Apps |
|---|---|
| 1798 | 1 |
| 1618 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18549899 | EX VIVO METHOD FOR ANALYSING A TISSUE SAMPLE USING PROTEOMIC PROFILE MATCHING, AND ITS USE FOR THE DIAGNOSIS, PROGNOSIS OF PATHOLOGIES AND FOR PREDICTING RESPONSE TO TREATMENTS | GZYBOWSKI, MICHAEL STANLEY | 1798 | §101§103§112 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 17778941 | BIOCOMPATIBLE OILY FERROFLUID AND PREPARATION PROCESS | DICKINSON, PAUL W | 1618 | §102§103 | Final Rejection | — | Pending | May 23, 2022 |
| 17593380 | CAPTURE OF MICROVESICLES FOR DIAGNOSTIC PURPOSES | COUGHLIN, MATTHEW P | 1626 | §112 | Final Rejection | 72d overdue | Pending | Sep 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCentre Hospitalier Universitaire De Bordeaux has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Michael Stanley Gzybowski has the most, with 1 of Centre Hospitalier Universitaire De Bordeaux's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
